Watson Pharmaceuticals receives FDA approval for generic Wellbutrin XL

Download PDF Copy

Reviewed

Nov 26 2008

Watson Pharmaceuticals, Inc. has announced that its subsidiary, Watson Laboratories, Inc., has received final approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets (XL) in the 150 mg strength.

Bupropion Hydrochloride Extended-Release Tablets is the generic equivalent to GlaxoSmithKline's Wellbutrin XL(R) product, which is indicated for the treatment of major depressive disorder. Watson intends to launch the product immediately.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

Source:

http://www.watson.com/

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Why Salmonella Dublin poses a food safety threat in beef and dairy

Scientists set out to map the world’s traditional food environments and their health impacts

Seattle’s Fresh Bucks program boosts food security and diet but benefits fade when funding ends

Food scientists identify worst additives for longevity: flavours, sweeteners, and colourings top list

Fast food’s grip on American diets weakens as younger adults cut back

UK food policy misses big slice of ultra-processed problem, study finds

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Brightly colored food and drinks hide synthetic dyes and lots of sugar

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.